Skip To The Main Content
Committee & Speaker Biographies

Committee & Speaker Biographies

2019 The Universe of Pre-filled Syringes & Injection Devices

22-23 October 2019, Gothenburg/Sweden

  • Mathias Romacker

    Mathias Romacker


    Mathias Romacker is Senior Director, Device Strategy at Pfizer HQ in New York City. He joined Pfizer in March 2015.

    In this commercial role, he focuses on the front end of device technology. He works with multiple functions and sites across the organization to develop a device strategy for Pfizer pipeline and inline products.

    Previously, for a duration of 9 years, Mathias worked in the device area for Amgen in Thousand Oaks, California. Before joining Amgen, he held multiple sales and marketing positions with Becton Dickinson and Gerresheimer in Germany, South Africa, and New Jersey. Mathias holds a Masters equivalent degree in economics from the University of Freiburg/Germany.

  • Schoenknecht_Thomas

    Thomas P. Schönknecht, PhD


    Thomas has profound experience in the device market with 25 plus years in the industry. He holds a Ph.D. in Biophysical Chemistry from the Max-Planck-Society and the University Goettingen, Germany and a Master’s degree in Chemistry from the University Goettingen.

    He is a frequent speaker, moderator and committee member at conferences regarding drug delivery and packing material science.

    Thomas was heading the PDA interest group for prefilled syringes and is currently active as PDA interest group leader combination products in Europe. In addition, he has been active as member in various DIN ISO committees regarding primary packaging materials and drug delivery devices.

  • Michael Betz

    Michael Betz, PhD

    F. Hoffmann-La Roche AG

    Dr. Michael Betz studied Chemistry at the University of Konstanz in Germany and, in 1989, he went to the Swiss Federal Institute of Technology (ETH), Zürich for his PhD at the Institute of Molecular Biology and Biophysics.

    Between 1994 and 1997 he later worked as a Postdoc in Prof. Robert Huber`s Structural Sciences Department at the Max-Planck-Institute of Biochemistry. Working for Sandoz, Johnson & Johnson and since 2013 for F. Hoffmann-La Roche AG in Basel, Michael gained a wealth of experience within the industry covering most aspects of protein handling and transferring biotech products into commercial manufacturing.

    He also got certified as Six Sigma Black Belt. Newest camera and illumination technology in combination with proven Deep Learning algorithms in the field of automated inspection systems provide a huge potential. Michael is currently transforming this potential into tangible productive innovation for the inspection network at Roche.

  • Mark Chipperfield

    Mark Chipperfield

    Corvus Device Limited

    Mark Chipperfield, Independent Consultant after 20+ years in operational and senior roles (GSK, Sanofi, Novartis, Roche).

    Working with different combi products (PFS/pens/AI, patch, pMDI/DPI, kits), Mark has deep experience with execution (due diligence/technical evaluation, design control phases to market; industrialisation; in-market maintenance; change and issues management) whilst in parallel establishing right-sized operational frameworks including business processes; QMS; org structure; facilities, etc. 

  • Jonas Fransson

    Jonas Fransson, PhD

    Swedish Orphan Biovitrum

    Dr Jonas Fransson is Director of Drug Product Development at Swedish Orphan Biovitrum AB, Stockholm, Sweden. He is trained at Uppsala University and received a Ph.D in pharmaceutics in 1996.

    Since then he has held various positions in the areas of formulation development and manufacturing focusing on product development of biologics. He has worked in a number of development projects covering conventional injectables, ophthalmic delivery, injection devices and lyophilization development. Dr Fransson is now at Sobi AB responsible for formulation, packaging and device development.

    Jonas is also engaged in various academic/industry collaborations and is chairman of the NextBioform consortium focusing on innovative methods for biological pharmaceuticals meeting end-user needs. Dr Fransson is also active in Sweden Drug Delivery.

  • Julia Häring

    Julia Häring, PhD

    Novo Nordisk

    Julia Häring is passionate about creating innovative offerings that make the lives of patients and caregivers easier.

    She has a leading role in the commercialisation and launch of Novo Nordisk’s digital health solutions. Her expertise is based on 12 years of experience from the pharmaceutical industry.

    Throughout her career she has worked with commercial strategy for early and late stage development projects with the ambition to embed commercial strategy in the development process.

    Her educational background is a MSc and a Ph.D. in Economics.

  • Philipp Hoerner

    Philipp Hoerner, PhD

    Bausch & Stroebel

    Philipp Hörner holds a degree in industrial engineering.

    In 2014, he joined Bausch + Ströbel Maschinenfabrik Ilshofen GmbH + Co. KG. He has several years of experience as a product manager in the business fields of syringe and cartridge processing.

    His main responsibilities are market analysis and initiating new product developments to meet future market trends.

    At B-S he is also in charge of supervising new primary packaging solutions in the market and act as a member of the DIN/ISO group for primary packaging.

  • Juan Kuang

    Juan C. Kuang


    Juan Kuang is Vice President, Final Drug Product Technologies at Amgen. He is accountable for primary container science, secondary packaging technologies, device engineering, and human factors design.

    Juan joined Amgen in 2011 where he provided leadership in Operations Improvement for the AML Drug Product organization. In August 2012, he was appointed head of Drug Product Manufacturing at Amgen in Puerto Rico where he delivered significant results in the launch of new products, reduction of non-conformances, normal scrap as well as cost per unit and overall budget spent. 

    Juan has a Bachelor’s degree in Mechanical Engineering from the University of Puerto Rico. He has been involved with various industry/professional organizations where he has been appointed as President of the Puerto Rico Medical Devices Cluster, member of the Board of Directors of the Puerto Rico Manufacturers Association (PRMA), and member of the Board of Directors of Biopharma.

  • Daniel Latham

    Daniel Latham, PhD


    Dr. Daniel Latham is the Head of Device Development & LCM,  where he leads an organisation of around 120 associates responsible for the development and life cycle management of delivery systems of drug/device combinations for new biologic entities, biosimilars, and cell & gene therapy.

    Over the past 13 years at Novartis, he has overseen many device and primary packaging developments, approvals and launches and has significantly supported the growth and understanding of device development and drug/device interaction within the organisation.

    Prior to Novartis, he held a variety of roles in consumer health­care, focusing on the development and marketing of OTC medicines, transdermal patches, and medical devices.

    He has a Ph.D. in controlled drug delivery from Queen Mary, Uni­versity of London and a Bachelor’s degree and Master’s degrees in Engineering and Medical Physics from the University of Sheffield’

  • Dennis Lee

    Dennis Lee, PhD

    Bill & Melinda Gates Foundation

    Dennis Lee is a Senior Program Officer in CMC at the Bill & Melinda Gates Foundation, where he provides product development support for vaccines and drugs, with a focus on long-acting and other advanced drug delivery technologies.

    He began his career as a medicinal chemist with the SmithKline Beecham (a GSK legacy company). In 1999, Dennis relocated to the San Francisco Bay area as Director of Chemistry at Sunesis Pharmaceuticals, a start-up that developed molecular fragment-based approaches for drug discovery. He returned to GSK in 2001, and headed medicinal chemistry in cardiovascular and urogenital diseases.

    Over the next several years, his group progressed several compounds into clinical development. In 2008, Dennis became Head of Chemistry and Preclinical Development in the new Ophthalmology unit at GSK. He contributed to the formation and evolution of the Ophthalmology business strategy, co-managed the discovery portfolio, and implemented and executed the drug delivery strategy for retinal diseases. He then joined GSK’s Discovery Partnerships with Academia, in which he and a group of senior drug discovery scientists identified and executed drug discovery collaborations with individual academic groups.

    In 2014, he became Director of Drug Delivery, Platform Technology and Sciences, a newly-formed drug delivery group, whose mission was to seek and develop novel drug delivery technologies that align with GSK’s portfolio. He relocated to Seattle to join the Gates Foundation in Jul 2018.

  • Yoshifumi Torii

    Yoshifumi Torii, PhD

    Fujifilm Kyowa Kirin Biologics Co., Ltd.

    Yoshifumi Torii received a PhD in Pharmacology from The University of Tokyo in 1994.

    He started his career in 1994 as a researcher at Pharmaceutical Research Laboratories of Kirin Brewery Co., Ltd., where he served in medical affairs, project management, strategic planning etc.

    He was seconded to Fujifilm Kyowa Kirin Biologics Co., Ltd. in 2013 as a General Manager of European Branch, and was appointed President in 2017.

  • Pascal Venneugues

    Pascal Venneugues, PhD

    European Medicines Agency

    Pascal Venneugues qualified as a pharmacist from the University of Paris, with a doctorate in the field of Molecular Genetics. He also holds masters’ degrees in Health Economics and in European Regulatory Affairs. From 2001 to 2003 he worked in pharmaceutical industry.

    He joined the European Medicines Agency in 2003 and works as Principal Scientist in Quality of Medicines, with a focus on Biologics.

  • Cathy Zhao

    Cathy Xia Zhao, PhD

    West Pharmaceutical Services

    Cathy Xia Zhao has over 15 years of experience in the medical/pharmaceutical industry. She is currently the Director of Scientific Insights Lab in West Pharmaceutical Services, Inc, and has held various positions in West prior, such as Global PPS Research Director. Before joing West, Cathy worked for BD as a Principal Materials Scientist.

    She received her Ph.D in Polymer Chemistry from City University of New York and her BS in Polymer Chemistry from the University of Science and Technology of China. Cathy is an inventor and holder of 14 US and European patents.